EA201792288A1 - Способы лечения рака - Google Patents

Способы лечения рака

Info

Publication number
EA201792288A1
EA201792288A1 EA201792288A EA201792288A EA201792288A1 EA 201792288 A1 EA201792288 A1 EA 201792288A1 EA 201792288 A EA201792288 A EA 201792288A EA 201792288 A EA201792288 A EA 201792288A EA 201792288 A1 EA201792288 A1 EA 201792288A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
treating cancer
folfiri
optionally
compound
Prior art date
Application number
EA201792288A
Other languages
English (en)
Inventor
Чиан Дж. ЛИ
Вэй Ли
Ючжи ЛИ
Лора Бородянски
Юань Гао
Дэвид П. Керштейн
Original Assignee
Бостон Биомедикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бостон Биомедикал, Инк. filed Critical Бостон Биомедикал, Инк.
Publication of EA201792288A1 publication Critical patent/EA201792288A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Способы, включающие введение по меньшей мере одного соединения формулы (I)FOLFIRI и, необязательно, по меньшей мере одного ингибитора ангиогенеза; и наборы, содержащие по меньшей мере одно соединение формулы (I)FOLFIRI и, необязательно, по меньшей мере один ингибитор ангиогенеза.
EA201792288A 2015-04-17 2016-04-18 Способы лечения рака EA201792288A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149349P 2015-04-17 2015-04-17
US201662281022P 2016-01-20 2016-01-20
PCT/US2016/028178 WO2016168857A1 (en) 2015-04-17 2016-04-18 Methods for treating cancer

Publications (1)

Publication Number Publication Date
EA201792288A1 true EA201792288A1 (ru) 2018-02-28

Family

ID=55910370

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792288A EA201792288A1 (ru) 2015-04-17 2016-04-18 Способы лечения рака

Country Status (16)

Country Link
US (2) US20180250260A1 (ru)
EP (1) EP3283071A1 (ru)
JP (2) JP2018511645A (ru)
KR (1) KR20180006919A (ru)
CN (1) CN107708700A (ru)
AU (1) AU2016249157A1 (ru)
BR (1) BR112017022269A2 (ru)
CA (1) CA2983011A1 (ru)
EA (1) EA201792288A1 (ru)
HK (1) HK1250942A1 (ru)
IL (1) IL255018A0 (ru)
MX (1) MX2017013359A (ru)
PH (1) PH12017501880A1 (ru)
SG (1) SG11201708507SA (ru)
TW (1) TW201713328A (ru)
WO (1) WO2016168857A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
BR112015025347A2 (pt) 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
EP4072561A4 (en) * 2019-12-11 2023-11-29 Inspirna, Inc. CANCER TREATMENT METHODS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190429B1 (en) * 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
AU2011227023B2 (en) 2010-03-19 2015-05-28 Boston Biomedical, Inc. Novel methods for targeting cancer stem cells
RU2571661C2 (ru) 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
EP2681203A4 (en) 2011-03-04 2014-07-30 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd NOVEL 4,9-DIHYDROXY-NAPHTO [2,3-B] FURANS ESTERS FOR THERAPEUTIC TREATMENT OF DISEASES
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
WO2013172918A1 (en) * 2012-05-15 2013-11-21 University Of Southern California Ksr1 gene polymorphism for use in predicting outcome and therapy selection
BR112015025347A2 (pt) 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer

Also Published As

Publication number Publication date
WO2016168857A1 (en) 2016-10-20
US20180250260A1 (en) 2018-09-06
PH12017501880A1 (en) 2018-03-05
EP3283071A1 (en) 2018-02-21
MX2017013359A (es) 2018-08-01
SG11201708507SA (en) 2017-11-29
KR20180006919A (ko) 2018-01-19
BR112017022269A2 (pt) 2018-07-10
US20190231735A1 (en) 2019-08-01
JP2020169222A (ja) 2020-10-15
CN107708700A (zh) 2018-02-16
IL255018A0 (en) 2017-12-31
TW201713328A (zh) 2017-04-16
CA2983011A1 (en) 2016-10-20
JP2018511645A (ja) 2018-04-26
AU2016249157A1 (en) 2017-11-02
HK1250942A1 (zh) 2019-01-18

Similar Documents

Publication Publication Date Title
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
EA201792229A1 (ru) Ингибиторы бромодомена
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
EA201690027A1 (ru) Ингибиторы ido
CR20200362A (es) CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
EA201690306A1 (ru) Ингибиторы ido
EA201591599A1 (ru) Ингибиторы ido
EA201792287A1 (ru) Способы лечения рака
EA201791390A1 (ru) Способ получения соединения диарилтиогидантоина
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201591705A1 (ru) Композиции и способы для диагностики и лечения рака печени
PH12017501880A1 (en) Methods for treating cancer
EA201592108A1 (ru) Гетероциклические соединения в качестве ингибиторов сигнального пути hedgehog
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201791391A1 (ru) Способы получения соединения диарилтиогидантоин
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
EP4306173A3 (en) Compositions and methods for treating cancers